Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch (NASDAQ:VSTM)
· seekingalpha.com
Verastem is performing commercially with Avmapki Fakzynja Co-pack and advancing in the clinic with its KRAS G12D inhibitor. Learn why VSTM stock is a buy.
Verastem Inc. ( VSTM ) markets Avmapki Fakzynja Co-pack (avutometinib with defactinib) for certain ovarian cancer patients, and is developing a KRAS inhibitor i...